Publications
-
- Conference presentation
- [EASL 2024] Additive hepatoprotective effects of DA-1241, a novel GPR119 agonist, in combination with semaglutide in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH
-
- Conference presentation
- [AACR 2024] A first-in class SHP1 allosteric inhibitor, SB8091, shows a good efficacy and safety profile in preclinical models
-
- Conference presentation
- [AACR-NCI-EORTC 2023] A first-in class and highly selective SHP1 allosteric inhibitor exhibits robust anti-tumor immunity and synergizes with PD-1 blockade
-
- Conference presentation
- [ADA 2023] A Novel GLP1R/GCGR Dual Agonist, DA-1726 Elicits Weight Loss Superior to Semaglutide in Diet-Induced Obese Rats
-
- Conference presentation
- [ADA 2023] Differentiated Metabolic Effects of DA-1726, a Balanced GLP1R/GCGR Dual Agonist
-
- Conference presentation
- [AACR 2023] A novel AhR inhibitor ‘DA-4505’ enhanced the anti-cancer efficacy in combination with surgery, chemotherapy and pembrolizumab through increasing cytotoxic effects with antigen presentation.
-
- Conference presentation
- [AACR 2023] DA-4505, a novel small-molecule AhR antagonist, as a new therapeutic option of immunotherapies.
-
- Conference presentation
- [AD/PD 2023] Neuroprotective effect of DA-7503, a novel tau aggregation inhibitor, against okadaic acid-induced tauopathy in vitro and in vivo.
-
- Conference presentation
- [SITC 2022] Antitumor effect of DA-4507, a novel GCN2 inhibitor as an immunotherapy in the tumor microenvironment.
-
- Conference presentation
- [AAIC 2022] Discovery of DA-7503 as a novel tau-targeted therapeutic candidate for the treatment of AD.